Key Laboratory of Diagnostics Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Cancer Lett. 2015 Jun 28;362(1):61-9. doi: 10.1016/j.canlet.2015.03.018. Epub 2015 Mar 18.
Phospholipase Cε (PLCε), a key regulator of diverse cellular functions, has been implicated in various malignancies. Indeed, PLCε functions include cell proliferation, apoptosis and malignant transformation. Here, we show that PLCε expression is elevated in prostate cancer (PCa) tissues compared to benign prostate tissues. Furthermore, PLCε depletion using an adenovirally delivered shRNA significantly decreased cell growth and colony formation, arresting the PC3 and LNCaP cell lines in the S phase of the cell cycle. We also observed that PLCε was significantly correlated with Notch1 and androgen receptor (AR). Additionally, we demonstrate that the activation of both the Notch and AR signalling pathways is involved in PLCε-mediated oncogenic effects in PCa. Our findings suggest that PLCε is a putative oncogene and prognostic marker, potentially representing a novel therapeutic target for PCa.
磷酸脂酶 Cε(PLCε)是一种调节多种细胞功能的关键酶,它与多种恶性肿瘤相关。事实上,PLCε 的功能包括细胞增殖、凋亡和恶性转化。在这里,我们发现前列腺癌(PCa)组织中的 PLCε 表达水平高于良性前列腺组织。此外,使用腺病毒递送的 shRNA 使 PLCε 耗竭,显著降低了细胞生长和集落形成,使 PC3 和 LNCaP 细胞系停滞在细胞周期的 S 期。我们还观察到 PLCε 与 Notch1 和雄激素受体(AR)显著相关。此外,我们证明 Notch 和 AR 信号通路的激活都参与了 PLCε 在 PCa 中的致癌作用。我们的研究结果表明,PLCε 是一种潜在的癌基因和预后标志物,可能为 PCa 提供了一个新的治疗靶点。